60 Degrees Pharmaceuticals, Inc. (SXTP) IPO Stocks Price,News,Date& information

Company Description

The mission of 60 Degrees Pharmaceuticals, a growth-oriented specialty pharmaceutical company, is to further develop and market novel treatments for the prevention and treatment of infectious diseases using cutting-edge biological science and applied research.

Arakoda, a medication that prevents malaria and has been available since late 2019, has been given regulatory approval.

Arakoda and Celgosivir are currently being used in 60P’s pipeline development programmes for COVID-19, fungal, tick-borne, and other viral infections.

Pharmaceutical company 60 Degrees, Inc.

This is 60 Degrees Pharmaceuticals, Inc.’s initial offering of its stocks to the public. We are selling units, each of which includes a share of common stock and a warrant to buy a share of common stock. The units will not be certificated or offered as stand-alone securities and do not have any stand-alone rights. The warrants and the shares of common stock that make up the units are instantly divisible and will be issued separately in this transaction. Every warrant is immediately exercisable on the day it is issued, and it has a five-year expiration date.

Additionally, shares of common stock that would be issued upon warrant exercise are included in this offering. A book-entry form of the warrants will be issued in accordance with a best ipo.

60 Degrees Pharmaceuticals, Inc.

CountryUnited States
Founded2010
IPO DateJun 22, 2023
IndustryDrug Manufacturers – Specialty & Generic
SectorHealthcare
Employees2
CEOGeoffrey S. Dow

Contact Details

Address:1025 Connecticut Avenue NW Suite 1000
Washington, DC, 20036
United States
Phone(202) 327-5422
Website60degreespharma.com

Stock Details

Ticker SymbolSXTP
ExchangeNASDAQ
Fiscal YearJanuary – December
Reporting CurrencyUSD
IPO Price$5.30
CIK Code0001946563
Employer ID45-2406880
SIC Code2834

Key Executives

NamePosition
Geoffrey DowChief Executive Officer, President and Director
Tyrone MillerTreasurer
Bryan SmithChief Medical Officer

Income Statement (Annual)

Millions USD. Fiscal year is Jan – Dec.

Year20212020
Revenue6.352.55
Revenue Growth (YoY)149.18%
Cost of Revenue0.850.7
Gross Profit5.51.85
Selling, General & Admin1.121.46
Research & Development5.510.81
Operating Expenses6.632.26
Operating Income-1.12-0.42
Interest Expense / Income3.142.63
Pretax Income-4.25-3.03
Income Tax00
Net Income-4.26-3.05
Net Income Common-4.25-3.03
Gross Margin86.61%72.43%
Operating Margin-17.69%-16.40%
Profit Margin-66.93%-119.00%
Free Cash Flow Margin-10.77%-9.35%
EBITDA-0.450.04
EBITDA Margin-7.05%1.39%
Depreciation & Amortization0.680.45
EBIT-1.12-0.42
EBIT Margin-17.69%-16.40%

Balance Sheet (Annual)

Millions USD. Fiscal year is Jan – Dec.

Year20212020
Cash & Equivalents0.120.19
Cash & Cash Equivalents0.120.19
Cash Growth-39.80%
Receivables0.150.86
Inventory0.691.04
Other Current Assets0.220.35
Total Current Assets1.172.44
Property, Plant & Equipment0.050.07
Goodwill and Intangibles0.170.08
Other Long-Term Assets0.010.01
Total Long-Term Assets0.220.16
Total Assets1.392.61
Accounts Payable0.541.38
Current Debt0.090.05
Other Current Liabilities00
Total Current Liabilities0.641.43
Long-Term Debt18.7619.14
Other Long-Term Liabilities0.150.1
Total Long-Term Liabilities18.9119.24
Total Liabilities19.5520.68
Total Debt18.8519.19
Debt Growth-1.78%
Common Stock4.40.23
Retained Earnings-22.63-18.38
Comprehensive Income0.080.08
Shareholders’ Equity-18.15-18.07
Net Cash / Debt-18.74-19
Working Capital0.541.01

Cash Flow Statement (Annual)

Millions USD. Fiscal year is Jan – Dec.

Year20212020
Net Income-4.25-3.03
Depreciation & Amortization0.680.45
Other Operating Activities2.932.43
Operating Cash Flow-0.65-0.17
Capital Expenditures-0.04-0.07
Investing Cash Flow-0.04-0.07
Debt Issued / Paid0.610.28
Financing Cash Flow0.610.28
Net Cash Flow-0.08-0.1
Free Cash Flow-0.68-0.24
Free Cash Flow Margin-10.77%-9.35%

Ratios and Metrics (Annual)

Millions USD. Fiscal year is Jan – dec

YearCurrent20212020
Market Capitalization30
Enterprise Value51
Debt / Equity Ratio-0.97-1.04-1.06
Debt / EBITDA Ratio-30.05-42.11541.02
Debt / FCF Ratio-17.14-27.54-80.55
Quick Ratio0.300.410.73
Interest Coverage-0.49-0.36-0.16

Total Valuation

SXTP has a market cap or net worth of $29.52 million. The enterprise value is $50.65 million.

Market Cap29.52M
Enterprise Value50.65M

Important Dates

Earnings Daten/a
Ex-Dividend Daten/a

Share Statistics

SXTP has 5.57 million shares outstanding.

Shares Outstanding5.57M
Shares Change (YoY)n/a
Shares Change (QoQ)n/a
Owned by Insiders (%)n/a
Owned by Institutions (%)n/a
Floatn/a

Valuation Ratios

PE Ration/a
Forward PEn/a
PS Ratio34.93
Forward PSn/a
PB Ration/a
P/FCF Ration/a
PEG Ration/a

require more information please comment

Leave a Comment